LISBON, Portugal – June 2019:Opioids and synthetic opioids, the continued growth of Europe’s cocaine market and implications of cannabis policy developments and the dynamics of the new psychoactive substances (NPS) market are among the issues addressed in the “European Drug Report 2019: Trends and Developments”, launched by the European Centre for Drugs and Drug Addiction (EMCDDA).

By the end of 2018, the EMCDDA monitored more than 730 NPS, 55 of which were detected for the first time in Europe in 2018. Moreover, in 2017, close to 64,160 NPS seizures were reported to the EU Early Warning System from across Europe. In Europe, NPS seizures are typically dominated by synthetic cannabinoids and cathinones, however the quantity of synthetic opioid and benzodiazepine seized appears to have increased in recent years.

Globally, UNODC monitors close to 900 NPS through the UNODC Early Warning Advisory on NPS. NPS have emerged worldwide in 117 countries and territories.

Source: EMCDDA: “European Drug Report 2019: Trends and Developments”

For more information please see:
EMCDDA report on “European Drug Report 2019: Trends and Developments”